Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid

Neuroendocrinology Letters

Volumn 30, Issue 5, 2009, Pages 647-651

  Talab, Radomír ^a   Valis, Martin ^a   Rehak, Svatopluk ^a   Andrys, Ctirad ^a   Krejsek, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer dementia; Beta amyloid; Biomarkers of axonal destruction; Brain injury; Cerebrospinal fluid; CJD; Hydrocephalus; Multiple sclerosis; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADOLESCENT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN TUMOR; BRAIN VENTRICLE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; HYDROCEPHALUS; LUMBAR PUNCTURE; MALE; NEUROSURGERY; PILOT STUDY; PRESCHOOL CHILD; PROTEIN CEREBROSPINAL FLUID LEVEL; SURGICAL DRAINAGE; VERTEBRAL CANAL;

EID: 77649260334     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K (2001). Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem. 267: 37967-37973.
2. Baloui H, Von Boxberg Y, Vinh J, Weiss S, Rossier J, et al (2004). Cellular prion protein/laminin receptor: Distribution in adult central nervous system and characterization of an isoform associated with a subtype of cortical neurons. Eur J Neurosci. 20(10): 2605-2616.
3. Brettschneider J, Maier M, Arda S, Claus A, Sussmuth SD, Kassubek J, et al (2005). Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler. 11: 261-265.
4. Goedert M, Klug A, Crowther R (2006). Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis. 9: 197-207.
5. Guimarǎes I, Cardoso MI, Sa MJ (2006). Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler. 12: 354-356.
6. Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's disease. Neuromolecular Med. 4: 21-36.
7. Holmberg B, Johnels B, Blennow K, Rosengren L (2003). Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 18: 186-190.
8. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E (2001). Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 71: 401-403.
9. Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K (2000). CSF tau is increased in multiple sclerosis. Eur Neurol. 43: 228-232.
10. Ledesma M., Medina M, Avila J (1996). The in-vitro formation of recombinant tau polymer effect of phosphorylation and glycation. Mol Chem Neuropathol. 27: 249-258.
11. Lunque FA, Jaffe SL (2007). Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol. 79: 341-356.
12. Martinez-Yelamos A, Saiz A, Sanchez-Valle R, et al (2001). 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology. 57: 722-724.
13. Martinez-Yelamos A, Saiz A, Bas J, et al (2004). Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett. 363: 14-17.
14. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, et al (2000). Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jacob disease. Neurology. 54: 1099-1102.
15. Petzold A, Eikelenbom MI, Keir G, et al (2006). The new global multiple sclerosis severtity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler. 12: 325-328.
16. Rudick RA, Whitaker JN. Cerebrospinal fluid tests for multiple sclerosis. In Scheinberg P (1987). Neurology/neurosurgery update series. Vol. 7, CPEC. Princeton, NJ.
17. Sjögren M, Minthon L, Davidsson P, Granérus AK, Clarberg A, Vanderstichele H, et al (2000). CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 107: 563-579.
18. Small DH, McLean CA (1999). Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? J Neurochem. 73: 443-449.
19. Strozyk D, Blennow K, White LR, Launer LJ (2003). CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 60: 652-656.
20. Talab R, Valis M, Andrys C, Krejsek J (2003). Tau protein and beta amyloid-42 in the patients with AD and others neurological diseases Cesk Slov Neurol N, 66/99(3): 227(In Czech).
21. Talab R, Valis M, Andrys C, Talabova M, Krejsek J (2004). Tau protein and beta amyloid in cerebrospinal fluid in patients with multiple sclerosis. Journal of Neuroimmunology, 154 (1-2): 189.
22. Trapp BD, Peterson J, Ransohoff RM, et al (1998). Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 338: 278-285.
23. Valis M, Talab R, Andrys C, Stourac P, Masopust J, Kalnicka D, Waberzinek G, (2008). Tau protein, fosfo-tau protein and beta amyloid-42 in cerebrospinal fluid in patients with demetia and multiple sclerosis. Cesk Slov Neurol N. 71/104(3): 329-335 (In Czech).
24. Wolfe MS (2002). Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov. 1: 859-866.